Insurance Status is an Independent Predictor of Overall Survival in Patients With Stage III Non-small-cell Lung Cancer Treated With Curative Intent.

Autor: Rice SR; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD., Vyfhuis MAL; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD., Scilla KA; Department of Medicine, Division of Hematology/Oncology, University of Maryland School of Medicine, Baltimore, MD., Burrows WM; Department of Surgery, Division of Thoracic Surgery, University of Maryland School of Medicine, Baltimore, MD., Bhooshan N; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD., Suntharalingam M; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD., Edelman MJ; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA., Feliciano J; Department of Medicine, Division of Hematology/Oncology, Johns Hopkins Hospital, Baltimore, MD., Badiyan SN; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO., Simone CB 2nd; New York Proton Center, New York, NY., Bentzen SM; Department of Epidemiology and Biostatistics, University of Maryland School of Medicine, Baltimore, MD., Feigenberg SJ; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA., Mohindra P; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD. Electronic address: pranshumohindra@gmail.com.
Jazyk: angličtina
Zdroj: Clinical lung cancer [Clin Lung Cancer] 2020 May; Vol. 21 (3), pp. e130-e141. Date of Electronic Publication: 2019 Sep 18.
DOI: 10.1016/j.cllc.2019.08.009
Abstrakt: Introduction: Population studies suggest an impact of insurance status on oncologic outcomes. We sought to explore this in a large single-institution cohort of patients with non-small-cell lung cancer (NSCLC).
Materials and Methods: We retrospectively analyzed 342 consecutive patients (January 2000 to December 2013) curatively treated for stage III NSCLC. Patients were categorized by insurance status as uninsured (U), Medicare/Medicaid + Veterans Affairs (M/M + VA), or Private (P). The χ 2 test was utilized to compare categorical variables. The Kaplan-Meier approach and the Cox proportional hazard models were used to analyze overall survival (OS) and freedom from recurrence (FFR).
Results: Compared with M/M + VA patients, P insurance patients were more likely to be younger (P < .001), married (P < .001), Caucasian (P = .001), reside in higher median income zip codes (P < .001), have higher performance status (P < .001), and undergo consolidation chemotherapy (P < .001) and trimodality therapy (P < .001). Diagnosis to treatment was delayed > 30 days in U (67.3%), M/M + VA (68.1%), and P (52.6%) patients (P = .017). Compared with the M/M + VA and U cohorts, P insurance patients had improved OS (median/5-year: 30.7 months/34.2%, 19 months/17%, and 16.9 months/3.8%; P < .001) and FFR (median/5-year: 18.4 months/27.3%, 15.2 months/23.2%, and 11.4 months/4.8%; P = .012), respectively. On multivariate analysis, insurance status was an independent predictor for OS (P = .017) but not FFR.
Conclusion: Compared with U or M/M + VA patients, P insurance patients with stage III NSCLC were more likely to be optimally diagnosed and treated, resulting in a doubling of median OS for P versus U patients. Improved access to affordable health insurance is critical to combat inequities in access to care and has potential for improvements in cancer outcomes.
(Copyright © 2019 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: